Knight Therapeutics Inc.

Toronto Stock Exchange:GUD.TO

Location

Market Cap

USD 417.95 M

Share Price

USD 4.20

Avg Daily Volume

70,614

Change (1 day)

-0.70%

Change (1 year)

4.99%

Change (YTD)

13.05%

Knight Therapeutics Inc. Revenue for the year ending December 31, 2024: USD 258.02 M

Knight Therapeutics Inc. Revenue is USD 258.02 M for the year ending December 31, 2024, a 4.20% change year over year. Revenue is the total amount of money generated from the sales of goods or services by a company during a specific period.
  • Knight Therapeutics Inc. Revenue for the year ending December 31, 2023 was USD 247.63 M, a 14.34% change year over year.
  • Knight Therapeutics Inc. Revenue for the year ending December 31, 2022 was USD 216.56 M, a 12.50% change year over year.
  • Knight Therapeutics Inc. Revenue for the year ending December 31, 2021 was USD 192.49 M, a 22.93% change year over year.
  • Knight Therapeutics Inc. Revenue for the year ending December 31, 2020 was USD 156.58 M, a 328.80% change year over year.
Key data
Date Revenue Revenue Gross Profit Operating Income
Market news
Loading...
Toronto Stock Exchange: GUD.TO

Knight Therapeutics Inc.

CEO Ms. Samira Sakhia BCom, CA, CPA, MBA
IPO Date March 3, 2014
Location Canada
Headquarters 3400 De Maisonneuve Boulevard West
Employees 745
Sector 🏥 Health Care
Industries
Description

Knight Therapeutics Inc., a specialty pharmaceutical company, develops, acquires, in-licenses, out-licenses, markets, and distributes pharmaceutical and consumer health products, and medical devices in Canada, Latin America, and internationally. It offers Nerlynx for extended adjuvant breast cancer and metastatic breast cancer; Tafasitamab for relapsed or refractory diffuse large B-cell lymphoma; Pemigatinib to treat metastatic cholangiocarcinoma; Trelstar for advanced prostate cancer and for pain associated with endometriosis; Vidaza for myelodysplastic syndrome; Abraxane for metastatic pancreatic adenocarcinoma; Halaven for metastatic breast cancer and doft tissue sarcoma; and Lenvima for differentiated thyroid cancer, advanced renal cell cancer, and unresectable hepatocellular carcinoma. The company also provides Ladevina for multiple myeloma, myelodysplastic syndrome, mantle cell lymphoma, and follicular lymphoma; Zyvalix for metastatic prostate cancer; Karfib for relapsed or refractory multiple myeloma; Leprid for advanced prostate cancer; Rembre for chronic myeloid leukemia; Ambisome and Cresemba for fungal infection; Impavido for leishmaniasis; Exelon for mild to moderately severe dementia; and Ibsrela for the treatment of irritable bowel syndrome with constipation. In addition, it offers Salofalk for ulcerative colitis; Ursofalk to treat biliary cirrhosis; Imvexxy for moderate to severe dyspareunia; Bijuva for moderate to severe vasomotor symptoms associated with menopause in women with intact uteri; Fibridoner to treat idiopathic pulmonary fibrosis; Toliscrin DPI for pseudomonas aeruginosa lung infection in patients with cystic fibrosis; Toliscrin 1-2 for severe acute or resistant chronic infections; and Tobradosa Haler for chronic lung infections. Further, the company finances other life science companies; and invests in life sciences venture capital funds. Knight Therapeutics Inc. was incorporated in 2013 and is headquartered in Montreal, Canada.

Similar companies

LLY

Eli Lilly and Company

USD 792.30

1.83%

ABBV

AbbVie Inc.

USD 185.39

-0.09%

RO.SW

Roche Holding AG

USD 341.12

-1.04%

AZN.L

AstraZeneca PLC

USD 140.14

-0.36%

MRK

Merck & Co., Inc.

USD 79.67

-0.81%

AMGN

Amgen Inc.

USD 280.35

1.03%

PFE

Pfizer Inc.

USD 24.26

-0.21%

GILD

Gilead Sciences, Inc.

USD 105.93

-1.19%

SAN.PA

Sanofi

USD 95.90

-1.25%

BMY

Bristol-Myers Squibb Company

USD 46.68

-0.74%

4519.T

Chugai Pharmaceutical Co., Ltd.

USD 52.21

0.11%

GSK.L

GSK plc

USD 19.07

-0.64%

COR

Cencora, Inc.

USD 292.32

-0.61%

REGN

Regeneron Pharmaceuticals, Inc.

USD 520.29

-0.38%

600276.SS

Jiangsu Hengrui Medicine Co., Ltd.

USD 7.29

-1.15%

HLN.L

Haleon plc

USD 5.22

0.20%

4502.T

Takeda Pharmaceutical Company Limited

USD 30.06

0.25%

4568.T

Daiichi Sankyo Company, Limited

USD 22.75

-2.17%

UCB.BR

UCB SA

USD 196.91

2.58%

3692.HK

Hansoh Pharmaceutical Group Company Limited

USD 3.66

-2.04%

INSM

Insmed Incorporated

USD 104.85

-0.99%

TEVA.TA

Teva Pharmaceutical Industries Limited

USD 17.07

-0.24%

WST

West Pharmaceutical Services, Inc.

USD 221.02

-0.74%

SMMT

Summit Therapeutics Inc.

USD 21.27

1.67%

CIPLA.NS

Cipla Limited

USD 17.67

0.68%

UTHR

United Therapeutics Corporation

USD 285.97

-1.37%

DRREDDY.NS

Dr. Reddy's Laboratories Limited

USD 15.43

-1.05%

TORNTPHARM.NS

Torrent Pharmaceuticals Limited

USD 37.11

-1.05%

1177.HK

Sino Biopharmaceutical Limited

USD 0.65

-2.09%

1093.HK

CSPC Pharmaceutical Group Limited

USD 0.99

-2.38%

ZYDUSLIFE.NS

Zydus Lifesciences Limited

USD 11.40

0.64%

MANKIND.NS

Mankind Pharma Limited

USD 26.96

0.47%

ASND

Ascendis Pharma A/S

USD 173.00

-3.41%

VTRS

Viatris Inc.

USD 8.89

-0.67%

BMRN

BioMarin Pharmaceutical Inc.

USD 54.14

-1.01%

ORNBV.HE

Orion Oyj

USD 73.45

0.35%

LUPIN.NS

Lupin Limited

USD 22.53

0.16%

SOBI.ST

Swedish Orphan Biovitrum AB (publ)

USD 29.11

0.12%

IPN.PA

Ipsen S.A.

USD 119.73

0.43%

000963.SZ

Huadong Medicine Co., Ltd

USD 5.62

-0.40%

4151.T

Kyowa Kirin Co., Ltd.

USD 17.15

0.68%

2196.HK

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.

USD 2.07

-0.24%

2607.HK

Shanghai Pharmaceuticals Holding Co., Ltd

USD 1.51

-0.50%

ABBOTINDIA.NS

Abbott India Limited

USD 370.22

0.53%

4523.T

Eisai Co., Ltd.

USD 27.72

1.51%

002422.SZ

Sichuan Kelun Pharmaceutical Co., Ltd.

USD 4.89

0.65%

002294.SZ

Shenzhen Salubris Pharmaceuticals Co., Ltd.

USD 6.45

-0.50%

1099.HK

Sinopharm Group Co. Ltd.

USD 2.37

0.01%

600085.SS

Beijing Tongrentang Co., Ltd

USD 5.12

0.41%

1530.HK

3SBio Inc.

USD 2.80

-1.78%

StockViz Staff

June 26, 2025

Any question? Send us an email